VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers
Status:
Completed
Trial end date:
2017-12-20
Target enrollment:
Participant gender:
Summary
This is a 2-part, drug-drug interaction study to evaluate potential PK interactions after
single doses in Part 1 and multiple doses in Part 2. In Part 1, subjects will receive single
dose of 5 treatments in a cross-over design; in Part 2 subjects will receive treatment for 10
days.
Phase:
Phase 1
Details
Lead Sponsor:
Venatorx Pharmaceuticals, Inc.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)